Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
Open accessThe DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
Abstract Systemic sclerosis (SSc) is a complex, multiorgan, autoimmune disease. Lung fibrosis occurs in ∼80% of patients with SSc; 25% to 30% develop progressive interstitial lung disease (ILD). The pathogenesis of fibrosis in SSc-associated ILD (SSc-ILD) involves cellular injury, activation/differentiation of mesenchymal cells, and morphological/biological changes in epithelial/endothelial cells. Risk factors for progressive SSc-ILD include older age, male sex, degree of lung involvement on baseline high-resolution computed tomography imaging, reduced DlCO, and reduced FVC. SSc-ILD does not share the genetic risk architecture observed in idiopathic pulmonary fibrosis (IPF), with key risk factors yet to be identified. Presence of anti–Scl-70 antibodies and absence of anti-centromere antibodies indicate increased likelihood of progressive ILD. Elevated levels of serum Krebs von den Lungen-6 and C-reactive protein are both associated with SSc-ILD severity and predict SSc-ILD progression. A promising prognostic indicator is serum chemokine (C-C motif) ligand 18. SSc-ILD shares similarities with IPF, although clear differences exist. Histologically, a nonspecific interstitial pneumonia pattern is commonly observed in SSc-ILD, whereas IPF is defined by usual interstitial pneumonia. The course of SSc-ILD is variable, ranging from minor, stable disease to a progressive course, whereas all patients with IPF experience progression of disease. Although appropriately treated patients with SSc-ILD have better chances of stabilization and survival, a relentlessly progressive course, akin to IPF, is seen in a minority. Better understanding of cellular and molecular pathogenesis, genetic risk, and distinctive features of SSc-ILD and identification of robust prognostic biomarkers are needed for optimal disease management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S. R., Baron, M., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38098 · Cited by 3,409
Self-citationDenton, C. P., & Khanna, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30933-9 · Cited by 2,212
Self-citationCyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677 · cited 1×
“A modest benefit was also reported in TLC, dyspnea, skin thickening, and health-related quality of life (31, 32).”
Self-citationNintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Tyndall, A. J., Bannert, B., Vonk, M., Airò, P., Cozzi, F., Carreira, P. E., Bancel, D. F., Allanore, Y., Müller-Ladner, U., Distler, O., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.114264 · Cited by 1,443 · cited 1×
“were attributed to pulmonary fibrosis, making it the leading cause of mortality in this patient population (6).”
Self-citationInterstitial Lung Disease in Systemic Sclerosis: A Simple Staging System
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,230 · cited 4×
“HRCT imaging is routinely performed at most centers, and the findings can be integrated with pulmonary function test results as per the Limited/Extensive Staging System developed by Goh and colleagues for SSc-ILD (26).”
InfluentialSelf-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,078
Self-citationBouros, D., Wells, A. U., Nicholson, A. G., Colby, T. V., Polychronopoulos, V., Pantelidis, P., Haslam, P. L., Vassilakis, D. A., Black, C. M., & du Bois, R. M. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2106012 · Cited by 820
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2609 · Cited by 809
Hoyles, R. K., Ellis, R. W., Wellsbury, J., Lees, B., Newlands, P., Goh, N. S. L., Roberts, C., Desai, S., Herrick, A. L., McHugh, N. J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22204 · Cited by 732
Self-citationBleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730
Autoantibodies in Systemic Sclerosis
Steen, V. D. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.03.005 · Cited by 684
Khanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00232-4 · Cited by 683 · cited 2×
“Analysis of serum CCL18 was able to differentiate the impact of tocilizumab versus placebo in SSc with early ILD on FVC% (14).”
Self-citationPark, J. H., Kim, D. S., Park, I.-N., Jang, S. J., Kitaichi, M., Nicholson, A. G., & Colby, T. V. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200607-912oc · Cited by 597
MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
Juge, P.-A., Lee, J. S., Ebstein, E., Furukawa, H., Dobrinskikh, E., Gazal, S., Kannengiesser, C., Ottaviani, S., Oka, S., Tohma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801562 · Cited by 520
Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis
van Bon, L., Affandi, A. J., Broen, J., Christmann, R. B., Marijnissen, R. J., Stawski, L., Farina, G. A., Stifano, G., Mathes, A. L., Cossu, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1114576 · Cited by 453 · cited 10×
“secreted by plasmacytoid dendritic cells (45).”
InfluentialMacrophages: friend or foe in idiopathic pulmonary fibrosis?
Zhang, L., Wang, Y., Wu, G., Xiong, W., Gu, W., & Wang, C.-Y. (2018) · Respiratory Research · doi:10.1186/s12931-018-0864-2 · Cited by 375
Goh, N. S., Hoyles, R. K., Denton, C. P., Hansell, D. M., Renzoni, E. A., Maher, T. M., Nicholson, A. G., & Wells, A. U. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40130 · Cited by 354 · cited 1×
“FVC of >10% or a decline of 5% to 9% in FVC with a decrease in DLCO of>15% (30).”
Self-citationThe clinical relevance of autoantibodies in scleroderma.
Ho, K. T., & Reveille, J. D. (2003) · Arthritis Research · doi:10.1186/ar628 · Cited by 337 · cited 2×
“The presence of anti–Scl-70 antibodies and the absence of anticentromere antibodies in SSc indicate an increased likelihood of progressive ILD (20, 22, 37).”
Cellular interactions in the pathogenesis of interstitial lung diseases
Bagnato, G., & Harari, S. (2015) · European Respiratory Review · doi:10.1183/09059180.00003214 · Cited by 277
Khanna, D., Albera, C., Fischer, A., Khalidi, N., Raghu, G., Chung, L., Chen, D., Schiopu, E., Tagliaferri, M., Seibold, J. R., et al. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.151322 · Cited by 268
Self-citationDe Lauretis, A., Sestini, P., Pantelidis, P., Hoyles, R., Hansell, D. M., Goh, N. S. L., Zappala, C. J., Visca, D., Maher, T. M., Denton, C. P., et al. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120725 · Cited by 263
Self-citationPredictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung Disease
Winstone, T. A., Assayag, D., Wilcox, P. G., Dunne, J. V., Hague, C. J., Leipsic, J., Collard, H. R., & Ryerson, C. J. (2014) · Chest · doi:10.1378/chest.13-2626 · Cited by 249
Song, J. W., Do, K.-H., Kim, M.-Y., Jang, S. J., Colby, T. V., & Kim, D. S. (2009) · Chest · doi:10.1378/chest.08-2572 · Cited by 248
Stock, C. J., Sato, H., Fonseca, C., Banya, W. A. S., Molyneaux, P. L., Adamali, H., Russell, A.-M., Denton, C. P., Abraham, D. J., Hansell, D. M., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-201786 · Cited by 231
Self-citationPrasse, A., Pechkovsky, D. V., Toews, G. B., Schäfer, M., Eggeling, S., Ludwig, C., Germann, M., Kollert, F., Zissel, G., & Müller‐Quernheim, J. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22559 · Cited by 227 · cited 1×
“Serum CCL18 (chemokine [C-C motif] ligand 18), a macrophage 2–derived protein that is chemotactic for a number of immune cells, has also been shown to be a good prognostic marker, even after adjustment for baseline ILD severity (40, 41).”
Christmann, R. B., Sampaio‐Barros, P., Stifano, G., Borges, C. L., de Carvalho, C. R., Kairalla, R., Parra, E. R., Spira, A., Simms, R., Capellozzi, V. L., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38288 · Cited by 221 · cited 2×
“Increased expression of genes regulated by TGF-b has been confirmed in patients with progressive lung fibrosis (10).”
Arnett, F. C., Gourh, P., Shete, S., Ahn, C. W., Honey, R. E., Agarwal, S. K., Tan, F. K., McNearney, T., Fischbach, M., Fritzler, M. J., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.111906 · Cited by 215
BSR and BHPR guideline for the treatment of systemic sclerosis
Denton, C. P., Hughes, M., Gak, N., Vila, J., Buch, M. H., Chakravarty, K., Fligelstone, K., Gompels, L. L., Griffiths, B., Herrick, A. L., et al. (2016) · Rheumatology · doi:10.1093/rheumatology/kew224 · Cited by 215
Self-citationChilosi, M., Poletti, V., Murer, B., Lestani, M., Cancellieri, A., Montagna, L., Piccoli, P., Cangi, G., Semenzato, G., & Doglioni, C. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000032380.82232.67 · Cited by 212
Interstitial lung disease in connective tissue disease—mechanisms and management
Wells, A. U., & Denton, C. P. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.149 · Cited by 211 · cited 1×
“The degree of irreversible architectural disruption likely determines the progression or reversibility of the lung condition (9).”
Self-citationMacrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Schupp, J. C., Binder, H., Jäger, B., Cillis, G., Zissel, G., Müller-Quernheim, J., & Prasse, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116775 · Cited by 204
Volkmann, E. R., Tashkin, D. P., Sim, M., Li, N., Goldmuntz, E., Keyes-Elstein, L., Pinckney, A., Furst, D. E., Clements, P. J., Khanna, D., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213708 · Cited by 197
Self-citationHerzog, E. L., Mathur, A., Tager, A. M., Feghali‐Bostwick, C., Schneider, F., & Varga, J. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38702 · Cited by 193
Self-citationKahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0506oc · Cited by 190
Goh, N. S. L., Veeraraghavan, S., Desai, S. R., Cramer, D., Hansell, D. M., Denton, C. P., Black, C. M., du Bois, R. M., & Wells, A. U. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22696 · Cited by 177 · cited 1×
“Currently, BAL is not routinely performed in patients with SSc-ILD; the previously observed link between BALF neutrophilia andmortality was subsequently found to bemainly related to disease severity (51, 52).”
Self-citationTruchetet, M.-E., Brembilla, N. C., Montanari, E., Allanore, Y., & Chizzolini, C. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3486 · Cited by 173
Elhaï, M., Hoffmann‐Vold, A., Avouac, J., Pezet, S., Cauvet, A., Leblond, A., Fretheim, H., Garen, T., Kuwana, M., Molberg, Ø., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40815 · Cited by 163 · cited 1×
“Serum CCL18 (chemokine [C-C motif] ligand 18), a macrophage 2–derived protein that is chemotactic for a number of immune cells, has also been shown to be a good prognostic marker, even after adjustment for baseline ILD severity (40, 41).”
Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease
Strange, C., Bolster, M. B., Roth, M. D., Silver, R. M., Theodore, A. C., Goldin, J. G., Clements, P. J., Chung, J., Elashoff, R. M., Suh, R. D., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-655oc · Cited by 156
Self-citationWu, W., Jordan, S., Becker, M. O., Dobrota, R., Maurer, B., Fretheim, H., Ye, S., Siegert, E., Allanore, Y., Hoffmann‐Vold, A., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213201 · Cited by 154 · cited 1×
“Other indices of SSc-ILD severity have also been associated with progressive disease, including the extent of disease on highresolution computed tomography (HRCT) imaging, reduced DLCO (% predicted), and decreased FVC (% predicted) (23, 24).”
Manetti, M., Guiducci, S., Romano, E., Bellando-Randone, S., Conforti, M. L., Ibba‐Manneschi, L., & Matucci‐Cerinic, M. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200837 · Cited by 126 · cited 1×
“Higher levels of MMP12 (matrix metalloproteinase-12) have been found in patients with SSc-ILD versus those without lung involvement; in the population with SSc-ILD, increased MMP12 levels appear to be associated with lower FVC (42).”
Khanna, D., Nagaraja, V., Tseng, C.-H., Abtin, F., Suh, R., Kim, G., Wells, A., Furst, D. E., Clements, P. J., Roth, M. D., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0872-2 · Cited by 125 · cited 1×
“Certain blood biomarkers may also be used to predict the risk of disease progression (27, 28), although they are not routinely used in clinical practice.”
Self-citationCXCL10 ( ) and CCL2 ( ) chemokines in systemic sclerosis a longitudinal study
Antonelli, A., Ferri, C., Fallahi, P., Ferrari, S. M., Giuggioli, D., Colaci, M., Manfredi, A., Frascerra, S., Franzoni, F., Galetta, F., et al. (2007) · Rheumatology · doi:10.1093/rheumatology/kem313 · Cited by 123
Regulatory T Cells in Systemic Sclerosis
Frantz, C., Auffray, C., Avouac, J., & Allanore, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02356 · Cited by 122
Kuwana, M., Shirai, Y., & Takeuchi, T. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.160339 · Cited by 120 · cited 1×
“Among biomarkers under clinical investigation, high plasma levels of KL-6 appear to be predictive of lung involvement and ILD progression in patients with SSc (23, 38, 39), including in SLS-II.”
Schmidt, K., Martinez-Gamboa, L., Meier, S., Witt, C., Meisel, C., Hanitsch, L. G., Becker, M. O., Huscher, D., Burmester, G. R., & Riemekasten, G. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2766 · Cited by 119 · cited 1×
“predictive biomarkers of SSc-ILD deterioration; this, however, has so far only been reported in small patient cohorts (54).”
MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis
Horimasu, Y., Ohshimo, S., Bonella, F., Tanaka, S., Ishikawa, N., Hattori, N., Kohno, N., Guzman, J., & Costabel, U. (2015) · Respirology · doi:10.1111/resp.12466 · Cited by 118
miR-155 in the progression of lung fibrosis in systemic sclerosis
Christmann, R., Wooten, A. K., Sampaio-Barros, P. D., Borges, C. L., de Carvalho, C. R. R., Kairalla, R. A., Feghali‐Bostwick, C. A., Ziemek, J., Mei, Y., Goummih, S., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1054-6 · Cited by 117 · cited 1×
“Studies have shown that increased expression of miR-155 is associated with worsened lung function and increased lung fibrosis (19).”
microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma
Sing, T., Jinnin, M., Yamane, K., Honda, N., Makino, K., Kajihara, I., Makino, T., Sakai, K., Masuguchi, S., Fukushima, S., et al. (2012) · Rheumatology · doi:10.1093/rheumatology/kes120 · Cited by 112
Interstitial lung disease in systemic sclerosis: current and future treatment
Giacomelli, R., Liakouli, V., Berardicurti, O., Ruscitti, P., Benedetto, P. D., Carubbi, F., Guggino, G., Bartolomeo, S. D., Ciccia, F., Triolo, G., et al. (2017) · Rheumatology International · doi:10.1007/s00296-016-3636-7 · Cited by 104 · cited 3×
“This leads to activation of the innate and adaptive immune system, recruitment and activation of fibroblasts, and differentiation of fibroblasts to a myofibroblast phenotype (7), with accumulation of ECM and development of fibrosis (8).”
Khanna, D., Yan, X., Tashkin, D. P., Furst, D. E., Elashoff, R. M., Roth, M. D., Silver, R. M., Strange, C., Bolster, M. B., Seibold, J. R., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22580 · Cited by 102
Self-citationLee, C. G., Herzog, E. L., Ahangari, F., Zhou, Y., Gulati, M., Lee, C.-M., Peng, X., Feghali-Bostwick, C., Jimenez, S. A., Varga, J., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201115 · Cited by 100 · cited 1×
“Levels of chitinase 1 have been reported to be significantly higher in patients with SSc-ILD than in patients with SSc and no lung involvement; as well as being a candidate biomarker, this enzyme could be considered as a therapeutic target (50).”
Self-citationVolkmann, E. R., Tashkin, D. P., Kuwana, M., Li, N., Roth, M. D., Charles, J., Hant, F. N., Bogatkevich, G. S., Akter, T., Kim, G., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41020 · Cited by 96 · cited 1×
“Among biomarkers under clinical investigation, high plasma levels of KL-6 appear to be predictive of lung involvement and ILD progression in patients with SSc (23, 38, 39), including in SLS-II.”
Self-citationWu, M., Baron, M. G., Pedroza, C., Salazar, G. A., Ying, B., Charles, J., Agarwal, S. K., Hudson, M., Pope, J. E., Zhou, X., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40171 · Cited by 94
Volkmann, E. R., Tashkin, D. P., Roth, M. D., Clements, P. J., Khanna, D., Furst, D. E., Mayes, M. D., Charles, J., Tseng, C., Elashoff, R. M., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1203-y · Cited by 91 · cited 2×
“Plasma CXCL4 levels reduced with immunosuppressive therapy; larger declines observed over the first 12 months of treatment were associated with greater improvements in lung function over the subsequent 12 months (47).”
Self-citationNordenbæk, C., Johansen, J. S., Halberg, P., Wiik, A., Garbarsch, C., Ullman, S., Price, P. A., & Jacobsen, S. (2005) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740510018598 · Cited by 87 · cited 1×
“Serum levels of chitinase-3–like protein 1, also known as YKL-40, have been shown to be higher in patients with SSc with versus those without pulmonary involvement (49).”
Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature
Bonhomme, O., André, B., Gester, F., de Seny, D., Moermans, C., Struman, I., Louis, R. E., Malaise, M., & Guiot, J. (2019) · Rheumatology · doi:10.1093/rheumatology/kez230 · Cited by 86
Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines.
Sharif, R. (2017) · PubMed · Cited by 77
pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis
Kafaja, S., Valera, I., Divekar, A., Saggar, R., Abtin, F. G., Fürst, D. E., Khanna, D., & Singh, R. R. (2018) · JCI Insight · doi:10.1172/jci.insight.98380 · Cited by 77
Self-citationYamakawa, H., Hagiwara, E., Kitamura, H., Yamanaka, Y., Ikeda, S., Sekine, A., Baba, T., Okudela, K., Iwasawa, T., Takemura, T., et al. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.48 · Cited by 74
Taniguchi, T., Miyagawa, T., Toyama, S., Yamashita, T., Nakamura, K., Saigusa, R., Ichimura, Y., Takahashi, T., Toyama, T., Yoshizaki, A., et al. (2018) · Experimental Dermatology · doi:10.1111/exd.13724 · Cited by 74 · cited 1×
“Fli1 appears to play a role in protecting against ILD, by upregulating the expression of genes, including autoimmune regulator and CXCL13 (7, 16).”
Clements, P. J., Goldin, J. G., Kleerup, E. C., Furst, D. E., Elashoff, R. M., Tashkin, D. P., & Roth, M. D. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20265 · Cited by 72
Self-citationRyerson, C. J., O’Connor, D., Dunne, J. V., Schooley, F., Hague, C. J., Murphy, D. T., Leipsic, J. A., & Wilcox, P. (2015) · CHEST Journal · doi:10.1378/chest.15-0003 · Cited by 71 · cited 1×
“Several models, including the Composite Physiologic Index; Interstitial Lung Disease–Gender, Age, Physiology Index; du Bois index; and modified du Bois index, have been reported to help predict mortality in patients with SSc-ILD (25).”
Peljto, A. L., Steele, M. P., Fingerlin, T. E., Hinchcliff, M., Murphy, E., Podlusky, S., Carns, M. A., Schwarz, M. I., Varga, J., & Schwartz, D. A. (2012) · CHEST Journal · doi:10.1378/chest.12-0110 · Cited by 69
Self-citationKhanna, D., Tashkin, D. P., Denton, C. P., Lubell, M., Vazquez‐Mateo, C., & Wax, S. D. (2018) · Rheumatology · doi:10.1093/rheumatology/key151 · Cited by 67
Self-citationWeigold, F., Günther, J., Pfeiffenberger, M., Cabral-Marques, O., Siegert, E., Dragun, D., Philippe, A., Regensburger, A.-K., Recke, A., Yu, X., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1545-8 · Cited by 65 · cited 1×
“Moreover, levels of antibodies against CXCL3 (chemokine [C-X-C motif] ligand 4) and CXCL4 have been reported to be increased in patients with SSc-ILD versus healthy control subjects but lower in patients with deteriorating versus stable lung function (48).”
Hou, Z., Ye, Q., Qiu, M., Hao, Y., Han, J., & Zeng, H. (2017) · Respiratory Research · doi:10.1186/s12931-017-0653-3 · Cited by 64
Recent Advances in Understanding the Pathogenesis of Scleroderma-Interstitial Lung Disease
Akter, T., Silver, R. M., & Bogatkevich, G. S. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-014-0411-1 · Cited by 59 · cited 10×
“Moreover, levels of thrombin are increased in the lungs of patients with SSc-ILD (7), probably as a consequence of cellular injury.”
InfluentialThe HLA Class II Allele DRB1*1501 Is Over-Represented in Patients with Idiopathic Pulmonary Fibrosis
Xue, J., Gochuico, B. R., Alawad, A. S., Feghali-Bostwick, C. A., Noth, I., Nathan, S. D., Rosen, G. D., Rosas, I. O., Dacic, S., Ocak, I., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014715 · Cited by 58
Kennedy, B., Branagan, P., Moloney, F., Haroon, M., O’Connell, O. J., O’Connor, T. M., O'Regan, K. N., Harney, S., & Henry, M. T. (2015) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 55
Kim, H. J., Tashkin, D. P., Gjertson, D. W., Brown, M. S., Kleerup, E. C., Chong, S., Belperio, J. A., Roth, M. D., Abtin, F. G., Elashoff, R. M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208929 · Cited by 55 · cited 1×
“Spontaneous regression can occur, albeit rarely, in SSc-ILD, and the disease course is likely to be stabilized by treatment with immunosuppressants or as part of natural history of the disease—changing from a declining trend to stability or, in a small percentage of cases, improving over time (13, 56).”
Self-citationLung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis
Cha, S., Chang, C. S., Kim, E. K., Lee, J. W., Matthay, M. A., Golden, J. A., Elicker, B. M., Jones, K., Collard, H. R., & Wolters, P. J. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04197.x · Cited by 53
Mak, A. C. Y., Tang, P. L. F., Cleveland, C., Smith, M. H., Connolly, M. K., Katsumoto, T. R., Wolters, P. J., Kwok, P., & Criswell, L. A. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39721 · Cited by 46
Hoffmann‐Vold, A., Weigt, S. S., Palchevskiy, V., Volkmann, E. R., Saggar, R., Li, N., Midtvedt, Ø., Lund, M. B., Garen, T., Fishbein, M. C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206545 · Cited by 44
The role of histology in idiopathic pulmonary fibrosis: An update
Cavazza, A., Rossi, G., Carbonelli, C. M., Spaggiari, L., Paci, M., & Roggeri, A. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.03.013 · Cited by 39
Conti, C., Montero-Fernandez, A., Borg, E., Osadolor, T., Viola, P., de Lauretis, A., Stock, C., Bonifazi, M., Bonini, M., Caramori, G., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201507-1322le · Cited by 37
Self-citationLandi, C., Bargagli, E., Carleo, A., Refini, R. M., Bennett, D., Bianchi, L., Cillis, G., Prasse, A., Bini, L., & Rottoli, P. (2018) · Rheumatology · doi:10.1093/rheumatology/key223 · Cited by 35
Interstitial lung disease in South Africans with systemic sclerosis
Ashmore, P., Tikly, M., Wong, M., & Ickinger, C. (2017) · Rheumatology International · doi:10.1007/s00296-017-3893-0 · Cited by 33 · cited 1×
“The presence of anti–Scl-70 antibodies and the absence of anticentromere antibodies in SSc indicate an increased likelihood of progressive ILD (20, 22, 37).”
Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management
Chowaniec, M., Skoczyńska, M., Sokolik, R., & Wiland, P. (2018) · Reumatologia/Rheumatology · doi:10.5114/reum.2018.77977 · Cited by 33 · cited 1×
“Elevated acute-phase reactants, such as high plasma C-reactive protein levels, have been associated with an increased likelihood of progressive early SSc-ILD (44).”
Circulating Biomarkers of Interstitial Lung Disease in Systemic Sclerosis
Lota, H., & Renzoni, E. A. (2012) · International Journal of Rheumatology · doi:10.1155/2012/121439 · Cited by 32
Self-citationStock, C. J. W., & Renzoni, E. A. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0104-8 · Cited by 30 · cited 3×
“SSc-ILD has been associated with a number of HLA-dependent genes and non-HLA genes (see Tables E1 and E2 in the online supplement) (15).”
InfluentialSelf-citationZhu, H., Zhu, C., Mi, W., Chen, T., Zhao, H., Zuo, X., Luo, H., & Li, Q. (2018) · International Journal of Rheumatology · doi:10.1155/2018/7342472 · Cited by 29 · cited 1×
“being underexpressed in patients with SScILD versus patients with SSc and no ILD (17).”
State of the Art. Mechanisms of Scleroderma-induced Lung Disease
du Bois, R. M. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200608-152ms · Cited by 29
Divekar, A., Khanna, D., Abtin, F. G., Maranian, P., Saggar, R., Saggar, R., Fürst, D. E., & Singh, R. R. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.08.010 · Cited by 22
Self-citationWu, M., Assassi, S., Salazar, G. A., Pedroza, C., Gorlova, O. Y., Chen, W. V., Charles, J., Taing, M. L., Liao, K., Wigley, F. M., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-0923-3 · Cited by 22
Self-citationRivière, S., Hua-Huy, T., TIEV, K. P., Cabané, J., & Dinh‐Xuan, A. T. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.170440 · Cited by 10
Cited by
Yang (2021) · doi:10.1038/s41598-020-79139-8 · Cited by 5,035
Wijsenbeek, M., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 539
Inoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133
Metadata
- Authors
- Khanna, D., Tashkin, D. P., Denton, C. P., Renzoni, E. A., Desai, S. R., & Varga, J.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-15
- Volume
- 201
- Issue
- 6
- Pages
- 650-660
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2995067265
- Cited by
- 195
- References
- 86
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.